Quiz on Guselkumab and Psoriatic Arthritis

Quiz on Guselkumab and Psoriatic Arthritis

University

10 Qs

quiz-placeholder

Similar activities

Éducation thérapeutique du Patient - Master ETP

Éducation thérapeutique du Patient - Master ETP

1st Grade - University

11 Qs

Colours and Flavours

Colours and Flavours

University

7 Qs

Ch15 Critical Thinking (Fundamentals)

Ch15 Critical Thinking (Fundamentals)

University

10 Qs

Examencito Presentación de Antígenos

Examencito Presentación de Antígenos

University

6 Qs

Quiz immuno

Quiz immuno

University

10 Qs

Pruebas cruzadas

Pruebas cruzadas

University

10 Qs

Antiretroviral

Antiretroviral

University

10 Qs

Patient Care Quiz Chp 11

Patient Care Quiz Chp 11

University

12 Qs

Quiz on Guselkumab and Psoriatic Arthritis

Quiz on Guselkumab and Psoriatic Arthritis

Assessment

Quiz

Science

University

Hard

Created by

Oscar Felipe-Díaz

FREE Resource

10 questions

Show all answers

1.

MULTIPLE CHOICE QUESTION

20 sec • 2 pts

What does the acronym ASDAS stand for?

Arthritis Severity Disease Assessment Score

Autoimmune Spondyloarthritis Disease Activity Score

Ankylosing Spondylitis Diagnostic Assessment Scale

Ankylosing Spondylitis Disease Activity Score

2.

MULTIPLE CHOICE QUESTION

20 sec • 3 pts

What is the primary aim of the post-hoc analysis in the DISCOVER studies?

To evaluate the safety of guselkumab

To assess the efficacy of guselkumab on axial involvement

To analyze the genetic factors in psoriatic arthritis

To compare different treatment methods for psoriatic arthritis

3.

MULTIPLE CHOICE QUESTION

10 sec • 1 pt

What percentage of patients in the analysis were male?

70%

61%

28%

39%

4.

MULTIPLE CHOICE QUESTION

30 sec • 1 pt

What was the primary characteristic of patients included in the post-hoc analysis?

They had no prior treatment for psoriatic arthritis

They had imaging-confirmed sacroiliitis

They were all HLA-B27 positive

They had a history of anti-TNF therapy

5.

MULTIPLE CHOICE QUESTION

30 sec • 1 pt

What was the mean age of the patients included in the analysis?

39.5 years

50.2 years

42.3 years

45.1 years

6.

MULTIPLE CHOICE QUESTION

20 sec • 5 pts

Which cytokine does guselkumab specifically target?

IL-6

TNF-alpha

IL-23

IL-17

7.

MULTIPLE CHOICE QUESTION

30 sec • 1 pt

What was the least squares mean change in BASDAI for the guselkumab every 4 weeks group at week 24?

-0.7

-2.7

-1.3

-1.4

Create a free account and access millions of resources

Create resources
Host any resource
Get auto-graded reports
or continue with
Microsoft
Apple
Others
By signing up, you agree to our Terms of Service & Privacy Policy
Already have an account?